Navigation Links
Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Date:6/12/2013

our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate a
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... on sophisticated equipment, trained personnel, and detection dogs ... terrorist attacks. A revolutionary new electronic chip with ... job much easier. , The groundbreaking nanotechnology-inspired sensor, ... University ,s School of Chemistry and Center for ... company Tracense, picks up the scent of explosives ...
(Date:7/24/2014)... and synthetic processes prefer to settle into equilibriuma ... is within the realm of non-equilibrium conditions where ... in energy and phases, such as temperature fluctuations, ... humans to regulate their body temperature, airplanes to ... activity. , But even though these conditions ...
(Date:7/24/2014)... , July 24, 2014 SRI International has ... the National Institute of Allergy and Infectious Diseases (NIAID), ... preclinical development of potential therapies for HIV infection and ... treat HIV and AIDS and the complications and opportunistic ... for preventing sexual transmission of HIV. ...
(Date:7/24/2014)...  Neogen Corporation (Nasdaq: NEOG ) advised ... revenue from new rodenticide research are premature. In its ... July 22, 2014, Neogen,s CEO commented about several new ... "It was my intent Tuesday at our conference ... new type of rodenticide, but certainly not to give ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Neogen comments on SenesTech 2
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today ... Stearns 20th Annual Healthcare Conference on September,11, 2007 at ... the Grand,Hyatt Hotel in New York City. Jack Lief, ... a corporate overview of the,company and its clinical development ...
... Vical Incorporated,(Nasdaq: VICL ) today announced ... Conference will be webcast live on Monday, September ... and Chief Executive Officer,Vijay B. Samant, will provide ... strategic partnerships. The webcast will be,available live and ...
... ... 2007--, PALO ALTO, Calif., ... data published in Circulation and,presented at the European Society of Cardiology Congress ... atrial arrhythmias in patients receiving Ranexa,compared to placebo in the MERLIN TIMI-36 ...
Cached Biology Technology:Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 3Vical to Present at Upcoming Investor Conferences 2Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R) 2Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R) 3Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R) 4
(Date:7/25/2014)... the way for the development of new lines of barley ... production is second only to wheat with 7-8 million tonnes ... diseases of barley. , Senior Research Scientist Dr Alan Little ... the cell walls of barley plants that block the penetration ... the ARC Centre of Excellence in Plant Cell Walls in ...
(Date:7/25/2014)... MOResearchers at the Stowers Institute for Medical Research ... pheromone receptors, and found pheromones crucial to triggering the ... of receptors helps a male mouse detect pheromones that ... of receptors lets him know if the female mouse ... pheromones are critical to trigger mating. Stowers, researchers believe ...
(Date:7/24/2014)... leads to conflict among people around the world, a ... Health & Ecosystems: Analysis of Linkages (HEAL) Program Director ... tackle global biodiversity decline. , The harvest of wild ... and provides protein for more than a billion of ... that today,s unprecedented loss of wildlife, is bringing with ...
Breaking Biology News(10 mins):New hope for powdery mildew resistant barley 2It takes two to court 2It takes two to court 3New study draws links between wildlife loss and social conflicts 2
... (December 2nd, 2011) Most of us would agree that ... the journal Clinical Rehabilitation , published by SAGE, indicate ... on health grounds in Finland had no measurable effect. , ... rehabilitation, which followed 872 participants and their 2440 matched controls ...
... research hurdle to developing regenerative treatments for diabetes and ... amounts of endoderm cells from human pluripotent stem cells. ... can be transferred to other areas of stem cell ... use known as the ,valley of death,. "One ...
... implantable replacement cartilage, holding promise for knees, shoulders, ears ... Self-assembling sheets of mesenchymal stem cells permeated ... stiffer cartilage than previous tissue engineering methods, researchers at ... the research is published in the Journal of ...
Cached Biology News:Costly intervention program has no measurable effect on early retirement 2Costly intervention program has no measurable effect on early retirement 3Scalable amounts of liver and pancreas precursor cells created using new stem cell production method 2Engineering cartilage replacements 2Engineering cartilage replacements 3
... modern flow cytometer, a scientist can resolve ... with fluorescent probes. However, the emission spectra ... labeling are broader than the light collection ... Thus, the fluorescence signal of a dye ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
... ActiveSight, the leading provider of ... design, offers fragment-based screening services to ... screening involves the binding of drug-like ... crystallized protein drug targets, allowing scientists ...
...
Biology Products: